Humana (NYSE:HUM) Upgraded by Morgan Stanley to Overweight

Morgan Stanley upgraded shares of Humana (NYSE:HUMGet Rating) from an equal weight rating to an overweight rating in a report published on Tuesday, Marketbeat Ratings reports. They currently have $549.00 price objective on the insurance provider’s stock, up from their previous price objective of $494.00.

Other equities analysts have also issued reports about the company. Credit Suisse Group set a $548.00 price target on Humana in a research note on Tuesday, July 19th. Cowen increased their price target on Humana to $547.00 in a research note on Tuesday, August 9th. Wells Fargo & Company increased their price target on Humana from $512.00 to $514.00 and gave the company an overweight rating in a research note on Wednesday, May 25th. Deutsche Bank Aktiengesellschaft increased their price target on Humana from $450.00 to $514.00 in a research note on Thursday, July 28th. Finally, Loop Capital initiated coverage on Humana in a research note on Thursday, June 16th. They set a buy rating and a $510.00 price target for the company. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from, the company has a consensus rating of Moderate Buy and a consensus price target of $519.28.

Humana Stock Performance

NYSE HUM opened at $502.89 on Tuesday. The firm has a market cap of $63.64 billion, a price-to-earnings ratio of 20.53, a price-to-earnings-growth ratio of 1.49 and a beta of 0.77. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.73. The business has a 50-day moving average price of $486.51 and a 200-day moving average price of $460.00. Humana has a twelve month low of $351.20 and a twelve month high of $514.98.

Humana (NYSE:HUMGet Rating) last released its quarterly earnings data on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share for the quarter, topping analysts’ consensus estimates of $7.67 by $1.00. The firm had revenue of $23.66 billion during the quarter, compared to analyst estimates of $23.44 billion. Humana had a return on equity of 18.42% and a net margin of 3.52%. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.89 earnings per share. As a group, equities research analysts predict that Humana will post 25.04 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 30th will be paid a $0.7875 dividend. The ex-dividend date is Thursday, September 29th. This represents a $3.15 annualized dividend and a yield of 0.63%. Humana’s dividend payout ratio (DPR) is currently 12.86%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tcwp LLC bought a new stake in Humana during the 1st quarter valued at $25,000. Castleview Partners LLC boosted its position in Humana by 46,704.0% during the 2nd quarter. Castleview Partners LLC now owns 11,701 shares of the insurance provider’s stock valued at $25,000 after acquiring an additional 11,676 shares in the last quarter. Jones Financial Companies Lllp bought a new stake in Humana during the 2nd quarter valued at $29,000. WFA of San Diego LLC bought a new stake in Humana during the 2nd quarter valued at $30,000. Finally, Riverview Trust Co bought a new stake in Humana during the 1st quarter valued at $32,000. Institutional investors own 93.50% of the company’s stock.

Humana Company Profile

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.